Answers are grounded in this paper and cite their sources.
Introduction: Biological aging is a modifiable process contributing to functional decline and chronic disease risk. Multi-modal interventions targeting aging hallmarks have shown promise, yet human data integrating lifestyle, supplementation, and regenerative therapies remain limited. Methods: This single-arm, open-label pilot trial in 16 healthy adults aged 46-72 (14 completers) tested a 17-week multi-modal program integrating lifestyle optimization, targeted supplementation, and two intravenous infusions of autologous pro-regenerative cell-derived conditioned media (APRC-CM). Trial registration: ClinicalTrials.gov, NCT07322224. Results: The intervention improved clinical biomarkers and reduced biological-age measures (PhenoAge and an epigenetic DNA-methylation clock) despite the cohort's already healthy baseline (chronological age 59.3 years; PhenoAge 55.5 years; epigenetic age 57.9 years), consistent with a net reversal of biological age rather than merely a correction of age acceleration. PhenoAge declined by 2.0 years (p = 0.014), reaching 5.8 years below chronological age; epigenetic age decreased by 2.7 years (p = 0.003), widening the gap to 4.1 years. Exploratory response analysis revealed heterogeneity, with a larger-response subgroup showing a mean epigenetic-age reduction of 5.1 years versus 0.2 years in a smaller/no-response subgroup. Among baseline biomarkers, serum iron strongly predicted response: lower iron correlated with greater epigenetic-age reduction (r = 0.64; p = 0.013), identifying baseline iron status as a candidate prognostic biomarker of response. No adverse events were reported. Discussion: Such reductions in health-optimized individuals are notable and may indicate a lowering below expected norms rather than solely a correction of age acceleration. The observed response heterogeneity, together with baseline iron metabolism as a potential predictor of response, is hypothesis-generating and warrants validation in larger, controlled trials, particularly as this open-label, single-arm pilot lacked a control or sham comparator.
No takes yet. Share an insight, caveat, or question.
Ortega et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: